BMY - Bristol-Myers Squibb Company
49.65 +0.05 (0.10%)
After hours: 6:41PM EDT
| Previous Close | 49.86 |
| Open | 50.01 |
| Bid | 49.55 x 800 |
| Ask | 49.65 x 2900 |
| Day's Range | 49.47 - 50.11 |
| 52 Week Range | 44.30 - 67.16 |
| Volume | 11,327,638 |
| Avg. Volume | 18,885,726 |
| Market Cap | 80.979B |
| Beta (3Y Monthly) | 0.86 |
| PE Ratio (TTM) | 16.48 |
| EPS (TTM) | 3.01 |
| Earnings Date | Apr 25, 2019 |
| Forward Dividend & Yield | 1.64 (3.28%) |
| Ex-Dividend Date | 2019-01-03 |
| 1y Target Est | 56.70 |
Market Realist•4 hours agoAnalysts Have Revised BMY’s Target Price Downward in March
How Major Pharmaceutical Stocks Are Positioned This Month(Continued from Prior Part)Analysts’ recommendations and target priceAnalysts expect an upside potential of 13.72% for Bristol-Myers Squibb (BMY) based on the company’s closing price on
- Barrons.com•5 hours ago
Starboard Is Against the Bristol-Myers and Celgene Deal. Now It Gets Interesting.
Less than a month before shareholders vote on Bristol-Myers Squibb’s proposed take over of Celgene, activist hedge fund Starboard Value released a presentation detailing its opposition to the deal.
- TheStreet.com•6 hours ago
Bristol-Myers Pushes Celgene Deal, Starboard Hits Back, in $74B Takeover Spat
traded blows with activist investor Starboard Value LP Tuesday as the pair issued competing presentations linked to the pharmaceutical group's planned $74 billion takeover of cancer drug specialist Celgene Corp. Bristol Myers said the deal, which if first unveiled in early January, would mean give combined companies number one positions in oncology and cardiovascular drug sales, with a top five standing in immunology and inflammation and nine currency products with over $1 billion in sales. Starboard, for its part, opposes the deal, arguing Celgene is a company facing a "massive patent cliff" that will force it to replace some 60% of its revenues over the next seven years.
- Zacks•7 hours ago
Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer
Roche (RHHBY) gets an FDA approval of sBLA for Tecentriq in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).
- TheStreet.com•9 hours ago
Jim Cramer Breaks Down Tilray Earnings, Elon Musk's Twitter and Bristol-Myers
posted a wider-than-expected fourth quarter loss but said sales nearly tripled in a growing global market for medical marijuana. Tilray said earnings for the three months ending in December were pegged at a net loss of 33 cents per share, compared to a 4 cents per share profit from the same period in 2017, a figure it put down to "operating expenses related to growth initiatives, expansion of international teams and costs related to financings and M&A activities." Group sales, however, rose more than 200% to $15.5 million, while total kilogram equivalents increased nearly three-fold to 2,053 and the average net selling price rose 5.5% to $7.52 per gram, reported TheStreet's Martin Baccardax. Elon Musk is still in hot water with the SEC about his Twitter presence.
- American City Business Journals•9 hours ago
Bristol-Myers Squibb and Starboard Value square off over Celgene deal
Activist investor says Bristol-Myers' Celgene deal "is ill-advised and could destroy substantial value for shareholders"; Bristol-Myers argues the deal "is a financially and strategically compelling transaction."
- Zacks•10 hours ago
Large-Cap Pharmaceuticals Industry Outlook: A Recovery Ahead?
Large-Cap Pharmaceuticals Industry Outlook: A Recovery Ahead?
- PR Newswire•12 hours ago
Starboard Issues Investor Presentation Opposing Bristol-Myers Squibb's Ill-Advised Proposed Acquisition of Celgene
Mails Definitive Proxy Materials and a BLUE Proxy Card for Shareholders to Vote AGAINST the Proposed Transaction at the Upcoming Special Meeting Believes the Proposed Merger with Celgene is Not in the ...
- Business Wire•12 hours ago
Bristol-Myers Squibb Files Investor Presentation Highlighting Significant Benefits of Pending Transaction with Celgene
Bristol-Myers Squibb Company (BMY) today filed a new investor presentation with the Securities and Exchange Commission (SEC) in connection with its previously announced definitive merger agreement with Celgene Corporation (CELG). The investor presentation is available on the SEC’s website at www.SEC.gov and on Bristol-Myers Squibb’s website at https://www.bms.com/investors.html. The Celgene acquisition is a financially and strategically compelling transaction.
- Reuters•20 hours ago
U.S. FDA approves Roche's small cell lung cancer treatment
Swiss drugmaker Roche Holding AG's U.S. unit Genentech said on Monday its immunotherapy Tecentriq won approval for a tough-to-treat type of lung cancer, the latest win for the drug whose sales trail medicines from Merck & Co and Bristol-Myers Squibb. The U.S. Food and Drug Administration (FDA) approved Tecentriq plus chemotherapy for untreated extensive-stage small cell lung cancer (SCLC), after a study showed patients getting the drug cocktail lived a median 12.3 months, compared to 10.3 months for those getting chemotherapy alone, Genentech said in a statement.
- Zacks•yesterday
Bristol-Myers & Pfizer Release Phase IV Data on Eliquis
Bristol-Myers (BMY) and partner Pfizer ) announce results from the phase IV - AUGUSTUS study evaluating Eliquis (apixaban) versus vitamin K antagonists (VKAs).
- Zacks•yesterday
Novartis' (NVS) Alcon Acquired PowerVision for $285 Million
Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.
- Business Wire•2 days ago
AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention
AUGUSTUS is the largest trial in this high-risk patient population requiring both anticoagulant and antiplatelet therapies
- Motley Fool•4 days ago
Is Celgene and Bristol-Myers a Match Made in Heaven or Doomed to Fail?
This mega-merger could be on the rocks following objections by high-profile investors.
- Zacks•4 days ago
Infinity Inks Deal With Roche for Phase II Study of IPI-549
Shares of Infinity (INFI) rise after the company inks deal with Roche to initiate a phase II MARIO-3 study on IPI-549. Per the deal, Roche will supply Tecentriq (atezolizumab) to Infinity.
- Zacks•4 days ago
Merck's Keytruda Gets EU Approval for Difficult Lung Cancer
Merck (MRK) receives approval for Keytruda's combo therapy for first-line treatment of metastatic squamous non-small cell lung cancer population in Europe.
- Zacks•4 days ago
Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others
Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.
- Simply Wall St.•4 days ago
Some Bristol-Myers Squibb (NYSE:BMY) Shareholders Are Down 25%
The simplest way to benefit from a rising market is to buy an index fund. But if you buy individual stocks, you can do both better or worse than that.Read More...
- Zacks•5 days ago
J&J Seeks Approval for Darzalex in Expanded Patient Group
J&J (JNJ) files sBLA seeking approval for Darzalex combination regimen in newly- diagnosed, transplant ineligible multiple myeloma patient population.
- Reuters•5 days ago
U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug
The U.S. patent office on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp's blockbuster myeloma drug Revlimid. Shares of Celgene were up 1.2 percent at $88.33 in early trading. The Patent Trial and Appeal Board, a court run by the U.S. patent office, said it was denying Alvogen's petition for an inter-partes review on the patents of the drug.
- Reuters•5 days ago
U.S. patent court rejects Alvogen's challenge for Celgene's Revlimid
A U.S. administrative court on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp's blockbuster myeloma drug Revlimid. The Patent Trial and Appeal Board, a court run by the U.S. patent office, said it was denying Alvogen's petition for an inter-partes review on the patents of the drug. Drugmaker Bristol-Myers Squibb Co in January said it would buy Celgene Corporation for about $74 billion, to expand its pipeline of cancer drugs.
- GuruFocus.com•6 days ago
5 Biotech Stocks to Keep an Eye on in 2019
The biotech sector is an interesting one to follow. Warning! GuruFocus has detected 2 Warning Sign with CELG. There has been quite a bit of chatter recently surrounding the potential acquisition of the company by Bristol-Myers Squibb (BMY).
- Barrons.com•6 days ago
Celgene’s Positive Drug Data Bolsters Bristol-Myers Deal, Analyst Says
Robert W. Baird analyst Brian Skorney wrote that neither company is “a coveted prize, but both are better off together than apart.” Celgene stock is up on upbeat FDA actions.
- Barrons.com•6 days ago
A Merck Cancer Treatment Has a Big Opportunity in China, Analyst Says
Cantor’s Louise Chen says the potential for Merck’s Keytruda in China could equate to billions of dollars not yet in forecasts.
- Markit•7 days ago
See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.
Bristol-Myers Squibb Co NYSE:BMYView full report here! Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low and declining Bearish sentimentShort interest | PositiveShort interest is low for BMY with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on March 4. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold BMY had net inflows of $4.43 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. BMY credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
